Medical Health & Life Science Research News

Research delivers insight into the insulin resistance global market

Medical Market Research

HTF Market Intelligence released a new research report of 45 pages on title 'Insulin Resistance - Pipeline Review, H1 2017' with detailed analysis, forecast and strategies. The study covers key regions and important players such as Amgen Inc, AusBio Ltd, F. Hoffmann-La Roche Ltd ..................

The latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H1 2017, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced.

Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure.

Predisposing factors include obesity and hypertension.


 Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to access

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Insulin Resistance - Overview

Insulin Resistance - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Resistance - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Resistance - Companies Involved in Therapeutics Development

Amgen Inc

AusBio Ltd

  1. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hadasit Medical Research Services & Development Ltd

Pfizer Inc

Prometheon Pharma LLC


Insulin Resistance - Drug Profiles

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A - Drug Profile

Product Description

Mechanism Of Action

View Detailed Table of Content at…e-pipeline-review





This email address is being protected from spambots. You need JavaScript enabled to view it.